We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Distribution Agreement for Brachytherapy

By MedImaging staff writers
Posted on 15 Aug 2005
Oncura (Philadelphia, PA, USA), a leader in the minimally invasive management of prostate cancer, has announced a worldwide agreement to distribute North American Scientific's (Chatsworth, CA, USA) palladium-103 prostate brachytherapy seeds, called Prospera.

The agreement, which starts on September 9, 2005, runs for five years, and allows Oncura to provide its customers with an uninterrupted supply of palladium-103 seeds. More...
The seed will be available in the full range of presentation options required by today's brachytherapy programs.

"Oncura has entered into this partnership to ensure that we fully satisfy the needs of all prostate brachytherapy customers,” stated James McGlone, president and CEO, Oncura. "We've increased our long-term commitment to the brachytherapy community and look forward to the opportunity of providing an enhanced level of service; this agreement will allow us to do so.”

The seeds have been supported by dosimetry studies recommended by the American Association of Physicists in Medicine (AAPM). Oncura will provide Prospera as a standard loose seed in their novel Strand, as well as in preloaded needles or Mick cartridges. Added to its range of iodine-125 products, Rapid Strand, OncoSeed, and EchoSeed, the introduction of Prospera will provide increased flexibility and convenience for all prostate brachytherapy programs.





Related Links:
Oncura
North American Scientifics'

Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Patient Monitoring System
AlarmSense
Radiofrequency Generator
GX1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.